The Long-term Complications of Covid-19 Infection DOI

Timothy J. Meagher

Journal of Insurance Medicine, Год журнала: 2024, Номер 51(2), С. 111 - 115

Опубликована: Июль 1, 2024

Context.— As the Covid-19 pandemic continues into its 4th year, reports of long-term morbidity and mortality are now attracting attention. Recent studies suggest that survivors at increased risk common illnesses, such as myocardial infarction, diabetes mellitus autoimmune disorders. Mortality may also be increased. This article will review evidence supports some these observations provide an opinion about their validity relevance to insured cohorts.

Язык: Английский

Understanding How Post–COVID-19 Condition Affects Adults and Health Care Systems DOI Creative Commons

Gabrielle M. Katz,

Katie Bach,

Pavlos Bobos

и другие.

JAMA Health Forum, Год журнала: 2023, Номер 4(7), С. e231933 - e231933

Опубликована: Июль 7, 2023

Importance Post–COVID-19 condition (PCC), also known as long COVID, encompasses the range of symptoms and sequelae that affect many people with prior SARS-CoV-2 infection. Understanding functional, health, economic effects PCC is important in determining how health care systems may optimally deliver to individuals PCC. Observations A rapid review literature showed hospitalization for severe critical illness limit a person’s ability perform day-to-day activities employment, increase their risk incident conditions use primary short-term services, have negative association household financial stability. Care pathways integrate care, rehabilitation specialized assessment clinics are being developed support needs However, comparative studies determine optimal models based on effectiveness costs remain limited. The likely large-scale associations economies will require substantial investment research, clinical policy mitigate these effects. Conclusions Relevance An accurate understanding additional at individual system levels informing resource planning, including identification affected by

Язык: Английский

Процитировано

46
Frequency and timing of adverse reactions to COVID-19 vaccines; A multi-country cohort event monitoring study DOI Creative Commons
Monika Raethke, Florence van Hunsel, Nicoletta Luxi

и другие.

Vaccine, Год журнала: 2024, Номер 42(9), С. 2357 - 2369

Опубликована: Март 6, 2024

During the COVID-19 pandemic, EMA set-up a large-scale cohort event monitoring (CEM) system to estimate incidence rates of patient-reported adverse drug reactions (ADRs) different vaccines across participating countries. This study aims give an up date and in-depth analysis frequency ADRs after 1st, 2nd, booster vaccination, identify potential predictors in developing describe time-to-onset (TTO) time-to-recovery (TTR) ADRs. A CEM was rolled out period ranging from February 2021 2023 multiple European countries; The Netherlands, Belgium, France, United Kingdom, Italy, Portugal, Romania, Slovakia Spain. Analysis consisted descriptive analyses frequencies vaccine-related for 2nd with generalized linear mixed-effects model, TTO TTR sensitivity loss follow-up (L2FU). total 29,837 participants completed at least baseline first questionnaire 1st vaccination 7,250 booster. percentage who reported one ADR is 74.32% (95%CI 73.82–74.81). Solicited ADRs, including injection site reactions, are very common moments. Potential these brand vaccine used, patient's age, sex prior SARS-CoV-2 infection. serious low (0.24%, 95%CI 0.19––0.31) (0.26%, 0.15, 0.41). 14 h (median) dose 1 slightly longer 2 dose. generally also within few days. effect L2FU on estimations limited. Despite some limitations due design study-roll out, studies can allow prompt almost real-time observations safety medications directly patient-centered perspective, which play crucial role regulatory bodies during emergency setting such as pandemic.

Язык: Английский

Процитировано

10
Long-term outcomes of the global tuberculosis and COVID-19 co-infection cohort DOI Creative Commons

Nicolás Casco,

Alberto Levi Jorge,

Domingo Palmero

и другие.

European Respiratory Journal, Год журнала: 2023, Номер 62(5), С. 2300925 - 2300925

Опубликована: Окт. 12, 2023

Background Longitudinal cohort data of patients with tuberculosis (TB) and coronavirus disease 2019 (COVID-19) are lacking. In our global study, we describe long-term outcomes affected by TB COVID-19. Methods We collected from 174 centres in 31 countries on all COVID-19 between 1 March 2020 30 September 2022. Patients were followed-up until cure, death or end time. All had COVID-19; for analysis purposes, deaths attributed to TB, both. Survival was performed using Cox proportional risk-regression models, the log-rank test used compare survival mortality Results Overall, 788 (active sequelae) recruited countries, 10.8% (n=85) died during observation period. significantly lower among whose versus those dying because either alone (p<0.001). Significant adjusted risk factors higher age (hazard ratio (HR) 1.05, 95% CI 1.03–1.07), HIV infection (HR 2.29, 1.02–5.16) invasive ventilation 4.28, 2.34–7.83). For mortality, risks 1.03, 1.02–1.04), male sex 2.21, 1.24–3.91), oxygen requirement 7.93, 3.44–18.26) 2.19, 1.36–3.53). Conclusions cohort, outcome >10% A range demographic clinical predictors associated adverse outcomes.

Язык: Английский

Процитировано

20
Direct and indirect effects of the COVID-19 pandemic on mortality in Switzerland DOI Creative Commons
Julien Riou, Anthony Hauser,

Anna Fesser

и другие.

Nature Communications, Год журнала: 2023, Номер 14(1)

Опубликована: Янв. 6, 2023

Abstract The direct and indirect impact of the COVID-19 pandemic on population-level mortality is concern to public health but challenging quantify. Using data for 2011–2019, we applied Bayesian models predict expected number deaths in Switzerland compared them with laboratory-confirmed from February 2020 April 2022 (study period). We estimated that COVID-19-related was underestimated by a factor 0.72 (95% credible interval [CrI]: 0.46–0.78). After accounting deaths, observed −4% CrI: −8 0) lower than expected. deficit concentrated age groups 40–59 (−12%, 95%CrI: −19 −5) 60–69 (−8%, −15 −2). Although control measures may have negative effects, after subtracting there were fewer during expected, suggesting any effects offset positive effects. These results important implications ongoing debate about appropriateness measures.

Язык: Английский

Процитировано

19
Long COVID: what is known and what gaps need to be addressed DOI Creative Commons
Benjamin A. Krishna, Mark R. Wills, Nyaradzai Sithole

и другие.

British Medical Bulletin, Год журнала: 2023, Номер 147(1), С. 6 - 19

Опубликована: Июль 11, 2023

Long COVID is a chronic condition that follows after acute COVID-19 and characterized by wide range of persistent, cyclic symptoms.

Язык: Английский

Процитировано

17
Mid- and long-term mortality risk factors after COVID-19 hospitalization: A retrospective observational study in Peru DOI Creative Commons
Max Carlos Ramírez-Soto, Hugo Arroyo-Hernández

Vaccine X, Год журнала: 2025, Номер unknown, С. 100631 - 100631

Опубликована: Март 1, 2025

Язык: Английский

Процитировано

0
Understanding the Post COVID-19 Condition (Long COVID) in Adults and the Expected Burden for Ontario DOI Creative Commons
Kieran L. Quinn,

Gabrielle M. Katz,

Pavlos Bobos

и другие.

Опубликована: Сен. 6, 2022

About Us: The Ontario COVID-19 Science Advisory Table is a group of scientific experts and health system leaders who evaluate report on emerging evidence relevant to the pandemic, inform Ontario's response.Our mandate provide weekly summaries for Health Coordination Province Ontario, integrating information from existing tables, universities agencies, best global evidence.The summarizes its findings public in Briefs.

Язык: Английский

Процитировано

21
Unmasking the COVID-19 pandemic prevention gains: excess mortality reversal in 2022 DOI Creative Commons
Marcin Piotr Walkowiak, Jan Domaradzki, Dariusz Walkowiak

и другие.

Public Health, Год журнала: 2023, Номер 223, С. 193 - 201

Опубликована: Сен. 5, 2023

The purpose of this study was to assess the long-term effectiveness COVID-19 pandemic prevention measures in saving lives after European governments began lift restrictions.Excess mortality interrupted time series.Country-level weekly data on deaths were fitted Poisson mixed linear model estimate excess deaths. Based estimate, percentage above baseline during (week 11 2020 week 15 2022) (when public health interventions place) and post-pandemic period 16 2022 52 calculated. These results regression determine any potential relationship between these two periods.The used had high predictive value (adjusted R2 = 59.4%). Mortality endemic (post-pandemic) alone increased by 7.2% (95% confidence interval [CI]: 5.7, 8.6) baseline, while each increase corresponded a 0.357% reduction CI: 0.243, 0.471) period.The most successful countries terms protective also experienced highest rates restrictions lifted. clearly shows measure bidirectional displacement that is sufficiently clear mask impact long COVID overall mortality. Results from seriously previous cost-benefit analyses measures, since, according current model, 12.2% 8.3, 16.1) gains achieved containment lost

Язык: Английский

Процитировано

10
LONG-COVID ТА АСОЦІЙОВАНІ УРАЖЕННЯ СЕРЦЕВО-СУДИННОЇ ТА НЕРВОВОЇ СИСТЕМ DOI Creative Commons
Vladyslav Svitailo,

М. Д. Чемич,

Oleksandr Saienko

и другие.

Інфекційні хвороби, Год журнала: 2023, Номер 4, С. 49 - 54

Опубликована: Апрель 14, 2023

З метою вивчення особливостей клінічного перебігу Long-COVID здійснили огляд наукових публікацій, які містять дані про як окремий патологічний стан, актуальну інформацію його прояви, та деякі патофізіологічні механізми, що призводять до розвитку уражень серцево-судинної і нервової систем. Висновки. Визначення терміну окремого стану у коронавірусної хвороби відбувалось кілька етапів. Симптоми пов’язані з ураженням майже всіх систем органів. Ураження системи є одними домінуючих, при цьому дані, механізм таких пов’язаний порушеннями системі згортання крові утворенням мікротромбів. Також ураження основною причиною смерті хворих Long-COVID. Співвідношення за статтю випадку однакове, той час системи, інших органів відбувається переважно жінок. Деякі існуючих даних вже знайшли додаткове підтвердження результатах останніх досліджень, інші потребують його.

Процитировано

9
Mortality in Norway and Sweden during the COVID-19 pandemic 2020–22: A comparative study DOI Creative Commons
Per‐Henrik Zahl,

Örjan Hemström,

Rune Johansen

и другие.

Journal of Infection and Public Health, Год журнала: 2023, Номер 17(4), С. 719 - 726

Опубликована: Ноя. 3, 2023

Norway and Sweden picked two different ways to mitigate the dissemination of SARS-CoV-2 virus. introduced strictest lockdown in Europe with strict border controls intense virus tracking all local outbreaks while did not. That resulted 477 COVID-19 deaths (Norway) 9737 (Sweden) 2020, respectively.

Язык: Английский

Процитировано

8